Stock Update: Eli Lilly & Company (NYSE:LLY) – New Study Shows Florbetapir F 18 Injection Scans Led to Change in Diagnosis and Management of Patients Being Evaluated for Cognitive Decline

[PR Newswire] – INDIANAPOLIS, July 22, 2015 /PRNewswire/ — Eli Lilly and Company (LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced new data showing that knowledge of amyloid . . . → Read More: Stock Update: Eli Lilly & Company (NYSE:LLY) – New Study Shows Florbetapir F 18 Injection Scans Led to Change in Diagnosis and Management of Patients Being Evaluated for Cognitive Decline Similar Articles: Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly Declares Second-Quarter 2015 Dividend Stock Update (NYSE:LLY): FDA recommends no changes to Lilly’s schizophrenia injection use